옵션 체인은 다양한 행사가격과 만기일에 대한 Sangamo Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Sangamo Therapeutics에 대한 시장 심리를 평가합니다..

Sangamo Therapeutics (NASDAQ:SGMO) 주식, 옵션 체인

Sangamo Therapeutics

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Earnings

News

Pre-Market Outlook

Markets

AMBO

CETX

CMPO

SGMO

화요일(31일) 아침 미국 주식 선물이 소폭 하락세를 보이는 가운데, 오늘 투자자들이 주목할 만한 주식은 다음과 같다. 화요일 주목해야 할 주식: 이항 홀딩스, 상가모 테라퓨틱스, 셈트렉스, 컴포시큐어 및 앰보우 에듀케이션

화요일 주목해야 할 주식: 이항 홀딩스, 상가모 테라퓨틱스, 셈트렉스, 컴포시큐어 및 앰보우 에듀케이션

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics Inc

According to multiple media reports on Thursday, Pfizer&nbsp;Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez.
In April 2024, the FDA approved Beqvez for moderate to severe hemophilia B in adult patients who currently use factor IX prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated,&nbsp;serious spontaneous&nbsp;bleeding episodes, and do not have neutralizing antibodies to&nbsp;adeno-associated&nbsp;virus&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38468053/fda-green-lights-pfizers-gene-therapy-for-rare-bleeding-disorder-hemophilia" rel="noreferrer noopener">serotype Rh74var capsid</a>.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43569013/uniqure-csl-behrings-hemophilia-gene-therapy-shows-sustained-efficacy-and-safety-at-four-years" rel="noreferrer noopener">uniQure/ CSL Behring&#8217;s Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years</a>
In a statement to&nbsp;Nikkei Asia, Pfizer <a target="_blank" href="https://asia.nikkei.com/Business/Pharmaceuticals/Pfizer-halts-work-on-hemophilia-gene-therapy" rel="noreferrer noopener">said</a> the decision was due to "the limited interest patients and their doctors have demonstrated in hemophilia gene therapies.&#8221;
The U.S. drugmaker said it would focus on different treatment for the disorder, citing low interest.
In December 2024, Pfizer walked away&nbsp;from its hemophilia A co-development pact with Sangamo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) giroctocogene fitelparvovec, an investigational gene <a target="_blank" href="https://www.benzinga.com/24/12/42740738/sangamo-therapeutics-stock-plunges-as-pfizer-terminates-hemophilia-gene-therapy-pact" rel="noreferrer noopener">therapy product candidate</a>.
According to a Reuters report, Pfizer will continue to invest resources in Hympavzi (marstacimab-hncq), which is approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients with hemophilia A or hemophilia B.
Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via a pre-filled,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41310468/fda-approves-pfizers-second-hemophilia-drug-with-six-months" rel="noreferrer noopener">auto-injector pen</a>.
Earlier this month, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with hemophilia A <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43557877/novo-nordisk-eyes-2025-regulatory-filing-for-hemophilia-candidate-after-encouraging-pediatric-study-data" rel="noreferrer noopener">with and without inhibitors</a>.
Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026.
In September 2024, Pfizer voluntarily withdrew all lots of Oxbryta&nbsp;(voxelotor) for sickle cell disease (SCD) in all markets&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41035514/pfizer-voluntarily-withdraws-all-lots-of-sickle-cell-disease-treatment-oxbryta-voxelotor-from-worl" rel="noreferrer noopener">where it is approved</a>.
Pfizer's decision is based on the totality of clinical data indicating that the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41048780/pfizer-voluntarily-withdraws-sickle-cell-disease-treatment-oxbryta-from-global-market-due-to-pain" rel="noreferrer noopener">cell patient population</a>.
Price Action: PFE stock is up 0.87% at $26.13 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43885302/apple-expands-apple-tv-to-android-eyes-subscription-growth-and-ecosystem-expansion-analyst-says" target="_blank" rel="noreferrer noopener">Apple Expands Apple TV+ to Android, Eyes Subscription Growth and Ecosystem Expansion, Analyst Says</a></li>
</ul>

Biotech

Large Cap

Health Care

General

Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes

Sangamo Therapeutics To Present Updated Phase 1/2 STAAR Study Data In Fabry Disease Showing Sustained Benefit, Improvements In Kidney Function And Favorable Safety Profile

In the last three months, 11 analysts have published ratings on Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Sangamo Therapeutics and provided 12-month price targets. The average target is $8.09, accompanied by a high estimate of $10.00 and a low estimate of $2.00. Surpassing the previous average price target of $7.73, the current average has increased by 4.66%.
<img src="https://www.benzinga.com/files/images/story/2025/1737982851_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Sangamo Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Maury Raycroft</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jim Birchenough</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sangamo Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sangamo Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Sangamo Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Sangamo Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SGMO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sangamo Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Sangamo Therapeutics's Background</h2>
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
<h3>Understanding the Numbers: Sangamo Therapeutics's Finances</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Sangamo Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 425.77%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Sangamo Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 18.99%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sangamo Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 29.88%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Sangamo Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.19% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 0.71, Sangamo Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and maintains $10 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

Truist Securities analyst Nicole Germino maintains Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and lowers the price target from $7 to $5.

Truist Securities Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $5

<h3>Gainers</h3>
<ul>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares rose 252.0% to $4.77 during Tuesday's pre-market session. The company's market cap stands at $26.0 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock rose 147.13% to $1.08. The company's market cap stands at $8.9 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock rose 99.2% to $0.23. The company's market cap stands at $25.1 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares moved upwards by 39.99% to $1.47. The market value of their outstanding shares is at $52.5 million. </li>
<li>Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares moved upwards by 33.51% to $4.9. The company's market cap stands at $218.0 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock rose 26.19% to $0.56. The market value of their outstanding shares is at $2.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares decreased by 53.4% to $1.09 during Tuesday's pre-market session. The market value of their outstanding shares is at $227.4 million. </li>
<li>Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) shares declined by 33.54% to $2.16. The market value of their outstanding shares is at $21.9 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) stock decreased by 18.56% to $0.61. The company's market cap stands at $63.3 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 18.21% to $0.37. The market value of their outstanding shares is at $3.0 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 10.65% to $1.93. The market value of their outstanding shares is at $8.0 million. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) stock fell 9.03% to $5.95. The company's market cap stands at $196.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BDMD

COCP

EYEN

LXEO

ONCO

PLRZ

SXTC

TLSA

VRPX

VSTM

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Jefferies analyst Maury Raycroft maintains Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and lowers the price target from $7 to $3.

Jefferies Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $3

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday.
The Dow traded down 0.26% to 42,461.52 while the NASDAQ fell 0.91% to 19,308.99. The S&amp;P 500 also fell, dropping, 0.55% to 5,874.24.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a>
Leading and Lagging Sectors Energy shares rose by 1.3% on Tuesday.
In trading on Tuesday, information technology shares fell by 1.2%.
Top Headline
The FHFA house price index rose by 0.4% in October versus market estimates of a 0.5% increase.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Aptorum Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares shot up 236% to $4.6052 after gaining 30% on Monday. Aptorum posted a H1 loss of 50 cents per share, versus a year-ago loss of $1.43 per share.</li>
<li>Shares of Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>)got a boost, surging 168% to $1.17. Onconetix recently announced it received a Nasdaq notice for a late quarterly report and subsequent filing.</li>
<li>ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) shares were also up, gaining 10% to $18.32. Acadia Pharmaceuticals will replace Independent Bank Group in S&amp;P SmallCap 600, effective prior to opening of trading on Jan. 3, 2025.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares dropped 56% to $1.03. On Monday, Sangamo Therapeutics regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).</li>
<li>Shares of Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) were down 25% to $2.60.</li>
<li>Cocrystal Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) was down, falling 36% to $2.09 after the company announced disappointing low infectivity rates for the Oral PB2 inhibitor CC-42344 and will extend its Phase 2a influenza challenge study.</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $71.79 while gold traded up 0.8% at $2,640.20.
Silver traded down 0.6% to $29.240 on Tuesday, while copper fell 1.7% to $4.0230.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.55% and France's CAC 40 rose 0.92%. Spain's IBEX 35 Index rose 0.50%, while London's FTSE 100 rose 0.64%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with China's Shanghai Composite Index falling 1.63%, Hong Kong's Hang Seng Index gaining 0.09% and India's BSE Sensex falling 0.14%.
Economics
<ul>
<li>The S&amp;P CoreLogic Case-Shiller home price index rose 4.2% year-over-year in October compared to a 4.6% increase in September, and versus market estimates of a 4.1% rise.</li>
<li>The FHFA house price index rose by 0.4% in October versus market estimates of a 0.5% increase.</li>
<li>The Dallas Fed general business activity index for Texas&#8217; service sector fell to 9.6 in December compared to 9.8 in November.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42739172/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 4% Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Trading Ideas

ACAD

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

9 analysts have shared their evaluations of Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $7.89, a high estimate of $10.00, and a low estimate of $2.00. Observing a 16.37% increase, the current average has risen from the previous average price target of $6.78. 
<img src="https://www.benzinga.com/files/images/story/2024/1735671620_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Sangamo Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jim Birchenough</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sangamo Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sangamo Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sangamo Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SGMO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sangamo Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Sangamo Therapeutics Better</h2>
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
<h3>A Deep Dive into Sangamo Therapeutics's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Sangamo Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 425.77%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Sangamo Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sangamo Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 29.88%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Sangamo Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of 9.19%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Sangamo Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.71, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

9 Analysts Have This To Say About Sangamo Therapeutics

U.S. stocks traded slightly lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday.
The Dow traded down 0.05% to 42,554.24 while the NASDAQ fell 0.23% to 19,441.37. The S&amp;P 500 also fell, dropping, 0.12% to 5,899.74.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a>
Leading and Lagging Sectors Energy shares rose by 1.1% on Tuesday.
In trading on Tuesday, utilities shares fell by 0.5%.
Top Headline
The FHFA house price index rose by 0.4% in October versus market estimates of a 0.5% increase.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Aptorum Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares shot up 380% to $6.58 after gaining 30% on Monday. Aptorum posted a H1 loss of 50 cents per share, versus a year-ago loss of $1.43 per share.</li>
<li>Shares of Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>)got a boost, surging 264% to $1.59. Onconetix recently announced it received a Nasdaq notice for a late quarterly report and subsequent filing.</li>
<li>ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) shares were also up, gaining 11% to $18.44. Acadia Pharmaceuticals will replace Independent Bank Group in S&amp;P SmallCap 600, effective prior to opening of trading on Jan. 3, 2025.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares dropped 54% to $1.07. On Monday, Sangamo Therapeutics regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).</li>
<li>Shares of Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) were down 22% to $2.72.</li>
<li>Cocrystal Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) was down, falling 37% to $2.05 after the company announced disappointing low infectivity rates for the Oral PB2 inhibitor CC-42344 and will extend its Phase 2a influenza challenge study.</li>
</ul>
Commodities In commodity news, oil traded up 1% to $71.68 while gold traded up 0.8% at $2,640.20.
Silver traded down 0.4% to $29.305 on Tuesday, while copper fell 1.7% to $4.0230.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.55% and France's CAC 40 rose 0.92%. Spain's IBEX 35 Index rose 0.50%, while London's FTSE 100 rose 0.64%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with China's Shanghai Composite Index falling 1.63%, Hong Kong's Hang Seng Index gaining 0.09% and India's BSE Sensex falling 0.14%.
Economics
<ul>
<li>The S&amp;P CoreLogic Case-Shiller home price index rose 4.2% year-over-year in October compared to a 4.6% increase in September, and versus market estimates of a 4.1% rise.</li>
<li>The FHFA house price index rose by 0.4% in October versus market estimates of a 0.5% increase.</li>
<li>The Dallas Fed general business activity index for Texas&#8217; service sector fell to 9.6 in December compared to 9.8 in November.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42739172/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 4% Dividend Yields</a></li>
</ul>

Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 0.2% on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.19% to 42,652.69 while the NASDAQ rose 0.04% to 19,495.43. The S&amp;P 500 also rose, gaining, 0.13% to 5,914.83.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a>
Leading and Lagging Sectors Energy shares rose by 0.9% on Tuesday.
In trading on Tuesday, information technology shares fell by 0.1%.
Top Headline
The S&amp;P CoreLogic Case-Shiller home price index rose 4.2% year-over-year in October compared to a 4.6% increase in September, and versus market estimates of a 4.1% rise.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Aptorum Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares shot up 263% to $4.98 after gaining 30% on Monday. Aptorum posted a H1 loss of 50 cents per share, versus a year-ago loss of $1.43 per share.</li>
<li>Shares of Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>)got a boost, surging 234% to $1.46. Onconetix recently announced it received a Nasdaq notice for a late quarterly report and subsequent filing.</li>
<li>Baird Medical Investment Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares were also up, gaining 252% to $3.70.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares dropped 48% to $1.2179. On Monday, Sangamo Therapeutics regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).</li>
<li>Shares of Energous Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) were down 43% to $1.5050 after jumping more than 550% on Monday.</li>
<li>Cocrystal Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) was down, falling 38% to $2.00 after the company announced disappointing low infectivity rates for the Oral PB2 inhibitor CC-42344 and will extend its Phase 2a influenza challenge study.</li>
</ul>
Commodities In commodity news, oil traded up 0.2% to $71.12 while gold traded up 0.3% at $2,626.30.
Silver traded down 0.3% to $29.325 on Tuesday, while copper fell 1.6% to $4.0285.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.4% and France's CAC 40 rose 0.9%. Spain's IBEX 35 Index rose 0.5%, while London's FTSE 100 rose 0.6%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with China's Shanghai Composite Index falling 1.63%, Hong Kong's Hang Seng Index gaining 0.09% and India's BSE Sensex falling 0.14%.
Economics
<ul>
<li>The S&amp;P CoreLogic Case-Shiller home price index rose 4.2% year-over-year in October compared to a 4.6% increase in September, and versus market estimates of a 4.1% rise.</li>
<li>The FHFA house price index rose by 0.4% in October versus market estimates of a 0.5% increase.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42739172/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 4% Dividend Yields</a></li>
</ul>

WATT

US Stocks Open Higher; House Prices Increase In October

On Monday, Sangamo Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
Pfizer decided to terminate the global collaboration and license agreement <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42733065/sangamo-therapeutics-to-regain-full-rights-to-hemophilia-a-gene-therapy-program-following-pfizers-" rel="noreferrer noopener">between the parties</a>. Sangamo intends to explore all options to advance the program, including seeking a potential new collaboration partner.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41310468/fda-approves-pfizers-second-hemophilia-drug-with-six-months" rel="noreferrer noopener">FDA Approves Pfizer&#8217;s Second Hemophilia Drug With Six Months</a>
In July 2024, Pfizer announced topline results from the Phase 3 AFFINE trial of giroctocogene fitelparvovec, which demonstrated that the trial met the primary and key secondary objectives of superiority <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39937203/sangamo-stock-spikes-as-pfizer-partnership-meets-goal-in-late-stage-study" rel="noreferrer noopener">compared to prophylaxis</a>.
&#8220;&#8230;we believe it is well positioned for regulatory submissions and potential commercialization,&#8221; said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. &#8220;While we were surprised and extremely disappointed by Pfizer&#8217;s decision to end our collaboration so close to the anticipated BLA and MAA submissions&#8230;&#8221;
The collaboration and license agreement with Pfizer will terminate effective April 21, 2025. All trial participants will continue to be monitored as planned during the transition period.
Sangamo believes that its recently announced partnerships with Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Genentech and Astellas Pharma Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALPMF#OTC">ALPMF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALPMY#OTC">ALPMY</a>) and advanced business development discussions for its Fabry gene therapy program will allow it to chart a path forward for its neurology genomic medicine pipeline.
The company prepares to initiate the expected enrollment of patients in the Phase 1/2 study of ST-503 for idiopathic small fiber neuropathy in mid-2025 and file an anticipated Clinical Trial Authorisation submission for the prion disease program in Q4 2025, each subject to securing additional funding.
Price Action: SGMO stock is down 54.70% at $1.106 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42727774/precigen-shares-surges-over-25-after-bla-submission-for-first-ever-rrp-gene-therapy" target="_blank" rel="noreferrer noopener">Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment</a></li>
</ul>

Contracts

ALPMF

ALPMY

RHHBY

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup cut the price target for Valley National Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLY#NASDAQ">VLY</a>) from $10.5 to $10. Citigroup analyst Ben Gerlinger maintained a Neutral rating. Valley National Bancorp shares closed at $9.12 on Monday. <a href="https://www.benzinga.com/quote/VLY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) price target from $3 to $2. Wells Fargo analyst Jim Birchenough maintained an Equal-Weight rating. Sangamo Therapeutics shares closed at $2.34 on Monday. <a href="https://www.benzinga.com/quote/SGMO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup raised the price target for Pinnacle Financial Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) from $123 to $132. Citigroup analyst Ben Gerlinger maintained a Buy rating. Pinnacle Financial Partners shares closed at $113.75 on Monday. <a href="https://www.benzinga.com/quote/PNFP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. raised the price target for Arqit Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) from $27 to $52. HC Wainwright &amp; Co. analyst Scott Buck maintained a Buy rating. Arqit Quantum shares closed at $43.32 on Monday. <a href="https://www.benzinga.com/quote/ARQQ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel cut Canoo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) price target from $4.5 to $0.5. Stifel analyst Stephen Gengaro downgraded the stock from Buy to Hold. Canoo shares settled at $1.37 on Monday. <a href="https://www.benzinga.com/quote/GOEV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel increased Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) price target from $153 to $175. Stifel analyst Thomas Stephan maintained a Buy rating. Glaukos shares closed at $149.51 on Friday. <a href="https://www.benzinga.com/quote/GKOS/analyst-ratings">See how other analysts view this stock.</a> </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

ARQQ

GKOS

GOEV

PNFP

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Tuesday.
Shares of Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) fell sharply in today's pre-market trading as the company announced its collaboration and license agreement with Pfizer on giroctocogene fitelparvovec <a href="https://www.benzinga.com/quote/SGMO/news">will terminate effective April 21, 2025.</a>
Sangamo Therapeutics shares dipped 50% to $1.17 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) dipped 13.8% to $5.32 in pre-market trading.</li>
<li>Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) fell 12.3% to $3.06 in pre-market trading after surging over 20% on Monday.</li>
<li>Arko Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKO#NASDAQ">ARKO</a>) fell 10% to $6.01 in pre-market trading.</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) fell 8.4% to $86.56 in pre-market trading. Dave issued a statement in response to amended FTC complaint and issued an update on new Extracash fee structure.</li>
<li>Senseonics Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SENS#NYSE">SENS</a>) declined 8.2% to $0.5050 in pre-market trading following a 7% drop on Monday.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) fell 5% to $8.14 in pre-market trading after declining around 6% on Monday.</li>
<li>Stevanato Group S.p.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) fell 2.6% to $20.99 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

ARKO

DAVE

DSGN

LAES

SENS

STVN

Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

WIIM

Sangamo Therapeutics shares are trading lower after Wells Fargo cut its price target on the stock from $3 to $2.

VRME: 253% &#x7C; <a href="https://www.benzinga.com//node/42733494">VerifyMe, Inc.: Stedham Adam H (Director, CEO and President) Buys 22,000 @ Avg Price: $0.71 (Form4)</a>
&nbsp;
NXU: 82% &#x7C; <a href="https://www.benzinga.com//node/42733027">Nxu Inc. files to sell 114.5M shares of Class A common stock for holders</a>
&nbsp;
SGMO: -64% &#x7C; <a href="https://www.benzinga.com//node/42733316">Sangamo Therapeutics Reveals Pfizer's Decision To Terminate Global Collaboration And License Agreement Between The Parties; Sangamo To Regain Full Rights to Hemophilia A Gene Therapy Program</a>
&nbsp;
&nbsp;

VRME

Market-Moving News for December 31st

Wells Fargo analyst Jim Birchenough maintains Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Equal-Weight and lowers the price target from $3 to $2.

Wells Fargo Maintains Equal-Weight on Sangamo Therapeutics, Lowers Price Target to $2

Shares of Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) rose sharply in today's pre-market trading after the company posted stronger-than-expected sales for the fourth quarter, reporting quarterly sales of $18.10 million which beat the analyst consensus <a href="https://www.benzinga.com/quote/CETX/earnings">estimate of $16.39 million</a>.
Cemtrex shares jumped 16.6% to $3.65 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) gained 135.7% to $0.2671 in pre-market trading after surging over 20% on Monday.</li>
<li>Aptorum Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) gained 86.1% to $2.55 in pre-market trading after gaining 30% on Monday. Aptorum posted a H1 loss of 50 cents per share, versus a year-ago loss of $1.43 per share.</li>
<li>Blue Hat Interactive Entertainment Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) rose 94.2% to $0.24 in pre-market trading after gaining around 6% on Monday.</li>
<li>IT Tech Packaging, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITP#NYSE">ITP</a>) gained 62.5% to $0.4711 in pre-market trading after gaining 7% on Monday.</li>
<li>Nxu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) gained 54% to $2.31 in pre-market trading after surging around 516% on Monday.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) rose 53.6% to $1.69 in pre-market trading after climbing around 15% on Monday.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) gained 46.9% to $1.91 in pre-market trading after gaining around 17% on Monday.</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) gained 41.1% to $1.27 in pre-market trading after gaining around 11% on Monday.</li>
<li>Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) gained 35.2% to $1.19 in pre-market trading after adding 85% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) fell 50% to $1.17 in pre-market trading as the company announced its collaboration and license agreement with Pfizer on giroctocogene fitelparvovec will terminate effective April 21, 2025.</li>
<li>Ambow Education Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#NYSE">AMBO</a>) shares tumbled 12.3% to $2.99 in pre-market trading after the company posted net income of $0.1 million for the second quarter, versus a year-ago net loss of $1.0 million. Its net revenues fell by 11.1% to $2.4 million during the quarter.</li>
<li>Energous Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) declined 28.3% to $1.90 in pre-market trading after jumping more than 550% on Monday.</li>
<li>Alset Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEI#NASDAQ">AEI</a>) shares dipped 20.5% to $1.01 in pre-market trading after jumping 52% on Monday.</li>
<li>The Real Good Food Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGF#NASDAQ">RGF</a>) fell 22.1% to $0.25 in pre-market trading as the company announced a reverse stock split.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares fell 21.2% to $0.6460 in pre-market trading after climbing 132% on Monday.</li>
<li>Inspired Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSE#NASDAQ">INSE</a>) shares fell 20.9% to $7.00 in pre-market trading.</li>
<li>Blackboxstocks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBX#NASDAQ">BLBX</a>) fell 14.2% to $2.29 in today's pre-market trading after jumping more than 62% on Monday.</li>
<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) dipped 13.8% to $5.32 in pre-market trading.</li>
<li>Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) fell 12.3% to $3.06 in pre-market trading after surging over 20% on Monday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

ASNS

BHAT

BLBX

BNAI

INSE

MULN

OPTT

Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

U.S. <a href="https://www.benzinga.com/24/12/42710703/sp-500-poised-for-best-year-vs-global-stocks-since-1997-bank-of-america-warns-of-2005-rotation">stock</a> futures were trading higher on Tuesday following Monday&#8217;s selloff. All four index futures rose in trade.
The Santa Rally, a typical year-end market surge, has seemingly failed to materialize this year, with stocks experiencing a downturn. However, the S&amp;P 500 index is on its way to achieving 20% plus return for the second consecutive year in 2024.
The 10-year and two-year Treasury notes yielded 4.51% and 4.24%, respectively. The probability of having no change in the interest rates for the upcoming Jan. 31, 2025, FOMC meeting was at 88.8%, <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">according to</a> CME Group&#8217;s FedWatch tool.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.40%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.29%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.18%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.38%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Tuesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.35% to $590.26 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.44% to $517.90, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
U.S. stocks <a href="https://www.benzinga.com/24/12/42736503/dow-tumbles-over-400-points-fear-continues-to-grip-markets-fear-greed-index-remains-in-fear-zone">declined </a>on Monday, with the Dow Jones Industrial Average falling over 400 points during the trading session. The tech sector continued its downward trend, with Tesla Inc. and Meta Platforms Inc. shares dropping 3.3% and 1.4%, respectively. 
Despite the Monday losses, major indices still posted gains for the previous week. The Dow Jones Industrial Average rose 0.4%, ending a three-week losing streak, while the S&amp;P 500 added 0.7% and the Nasdaq Composite climbed 0.8%.
On the economic data front, the Chicago Purchasing Managers&#8217; Index (PMI) fell to 36.9 in December from 40.2 in November, below market expectations of 42.5. Conversely, U.S. pending home sales increased 2.2% month-over-month in November, exceeding market estimates of a 0.7% increase. The Dallas Fed&#8217;s Texas manufacturing activity index also showed improvement, rising six points to a reading of 3.4 in December.
All sectors within the S&amp;P 500 closed lower, with consumer discretionary, materials, and healthcare sectors experiencing the largest declines.
At the close of trading on Monday, the Dow Jones Industrial Average stood at 42,573.73, down approximately 418 points. The S&amp;P 500 fell 1.07% to 5,906.94, and the Nasdaq Composite dipped 1.19% to 19,486.79.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-1.19%</td>
<td>19,486.78</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.07%</td>
<td>5,906.94</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.97%</td>
<td>42,573.73</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.75%</td>
<td>2,227.78</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Tom Lee, the head of research at Fundstrat attributed this decline to profit-taking and investor uncertainty surrounding the Federal Reserve&#8217;s future interest rate policies. However, he emphasizes that the positive market outlook for 2025 remains largely unchanged.
According to Lee, even if the S&amp;P 500 closes the year at 5,900, it doesn&#8217;t diminish the significant potential for growth in 2025.
Looking ahead to next year, Lee said that he will closely monitor the CEO confidence index and the ISM manufacturing data for signs of economic expansion. He predicts that the S&amp;P 500 could potentially reach 7,000 in the first half of 2025, representing substantial upside from current levels.
According to Ed Yardeni of Yardeni Research, there are multiple reasons for missing the Santa Rally. &#8220;From a sentiment perspective, there have been too many bulls. From a technical perspective, breadth has been narrowing again as a few LargeCap momentum stocks continue to outperform.&#8221;
&#8220;From a fundamental perspective, while earnings growth should remain bullish, the Fed may be done easing monetary policy for a while at the same time as the outlook for fiscal policy under Trump 2.0 is uncertain. From a valuation perspective, forward P/Es are stretched,&#8221; he added.
According to Jeff Weniger, the head of equities at WisdomTree, the S&amp;P 500 has had positive returns in the next 12 months each time economists&#8217; recession prediction has fallen to 15%.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The percentage of economists predicting recession has fallen to 15%, down from 47% in 2022. When it fell like this in 1970, 1975, 1983, 1992, 2002 and 2009, the S&amp;P 500 had positive returns in the following 12 months each time. Best wishes to all for a happy &amp; healthy 2025. <a href="https://t.co/Xarc8ohJFK">pic.twitter.com/Xarc8ohJFK</a>
&mdash; Jeff Weniger (@JeffWeniger) <a href="https://twitter.com/JeffWeniger/status/1873771253687029841?ref_src=twsrc%5Etfw">December 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Also, Jason Goepfert, consultant at White Oak Consultancy highlighted in an X post that S&amp;P 500 futures have gapped down more than 1% during the Santa Rally period for the fifth time in 2024.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This will be only the 5th time since the inception of S&amp;P 500 futures that they gapped down more than -1% during the Santa Rally period. It was a bad omen ahead of the pandemic (who knew), not so much the other times. <a href="https://t.co/QwV8kMb7cp">pic.twitter.com/QwV8kMb7cp</a>
&mdash; Jason Goepfert (@jasongoepfert) <a href="https://twitter.com/jasongoepfert/status/1873736244674580839?ref_src=twsrc%5Etfw">December 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
A few important data points will be released in this truncated week that will help investors determine the future course of action.
<ul>
<li>On Tuesday, November's S&amp;P Case-Shiller home price index for 20 cities will be announced at 9:00 a.m., ET.</li>
</ul>
<ul>
<li>No data is slated to be released on Wednesday, Jan. 1, owning to a New Year's holiday.</li>
</ul>
<ul>
<li>On Thursday, initial jobless claims till Dec. 28 will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Construction spending data for November will be released at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>On Friday, ISM manufacturing data for December will be announced at 10:00 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Sangamo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) was down 52.55% in premarket after it announced that its collaboration and license agreement with Pfizer on giroctocogene fitelparvovec will terminate effective April 21, 2025.</li>
</ul>
<ul>
<li>Cemtrex Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) was up 15.02% after it posted stronger-than-expected sales for the fourth quarter, reporting quarterly sales of $18.10 million which beat the analyst consensus estimate of $16.39 million.</li>
</ul>
<ul>
<li>CompoSecure Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) was up 4.47% after it announced plans to spin off Resolute Holdings Management.</li>
</ul>
<ul>
<li>Ambow Education Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#NYSE">AMBO</a>) was down 13.53% after its net revenue fell by 11.1% to $2.4 million during the quarter.</li>
</ul>
<ul>
<li>Faraday Future Intelligent Electric Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) was up 17.2% after the company disclosed on Sunday that entrepreneur Luke Hans will receive the first &#8216;FF 91&#8217; 2.0 Futurist Alliance EV of 2025 during a January delivery ceremony with company executives.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were higher in the early New York session by 0.56% to hover around $71.39 per barrel.
The gold spot index was up by 0.39% to $2,628.34 per ounce. The Dollar Index was down 0.17% to 107.944 level.
Asian markets were mostly lower on Tuesday as Japan&#8217;s Nikkei 225, Australia&#8217;s ASX 200, South Korea&#8217;s Kospi, and China&#8217;s CSI 300 declined. Whereas, Hong Kong&#8217;s Hang Seng ended higher. European markets were mixed.
Read Next:
<ul>
<li><a style="font-weight: bold;" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42720866/bond-vigilantes-send-loud-warning-message-as-treasuries-climb-to-may-highs-is-the-santa-rally-in-serious-doubt-heres-what-analysts-say">Bond Vigilantes Send &#8216;Loud Warning Message&#8217; As Treasuries Climb To May Highs: Is The Santa Rally In &#8216;Serious Doubt&#8217;? Here&#8217;s What Analysts Say</a></li>
</ul>
Photo courtesy: Wikimedia

Market Summary

Bonds

Futures

Economics

Federal Reserve

FFIE

TSLA

US Stocks Poised To Open Higher On Last Trading Day Of 2024: Analyst Sees S&P 500 At 7,000 In First Half Of 2025

Press Releases

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer's Decision to Cease Development of Giroctocogene Fitelparvovec

Penny Stocks

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

TYO:4503

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Sangamo Therapeutics

Sangamo Therapeutics (SGMO) 옵션

Sangamo Therapeutics (NASDAQ:SGMO) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌